

European LeukemiaNet Guidelines and Recommendations (2006 – 2014)

	Title	Publication	
ALL	Recommendations	Gökbuget N., (Book, Unimed)	[2]
	How I treat older patients with ALL	Gökbuget N., Blood 2013	[58]
AML	AML management recommendations	Döhner H., Blood 2009	[3]
	APL management recommendations	Sanz M., Blood 2009	[4]
	APL molecular monitoring	Grimwade D., JCO 2009	[5]
	HSCT for patients with AML in remission: an integrated-risk adapted approach	Cornelissen JJ, Nat.Rev. 2012	[42]
CLL	Guidelines	Hallek M., Blood 2008	[6]
	Molecular monitoring	Ghia P., Leukemia 2007	[7]
	Flow cytometry	Rawstron A. C., Leukemia 2007	[8]
	Recommendations on TP53 mutation analysis	Pospisilova S., Leukemia 2012	[9]
	Update flow cytometry in CLL	Rawstron A. C., Leukemia 2013	[43]
CML	Management recommendations	Baccarani M., Blood 2013 Baccarani M., JCO 2009 Hehlmann R., Lancet 2007 Baccarani M., Blood 2006	[60] [10] [11] [12]
	Statistical issues for phase III clinical trials in CML	Guilhot J., Blood 2012	[13]
	Statistical challenges arising from endpoints beyond overall survival in clinical trials on CML	Pfirschmann M., Leukemia 2011	[57]
	Validation of Analytical Reference Panels for the Standardization on the International Scale	White HE, Clin Chem. 2013	[44]
	Standardized definitions of molecular response in CML	Cross NC, Leukemia 2012	[45]
	Establishment of the first WHO International Genetic Reference Panel	White HE, Blood 2010	[46]
	Molecular monitoring	Müller M. C., Leukemia 2009 Branford S., Leukemia 2007 Hughes T., Blood 2006	[14] [15] [16]
	Mutational analysis	Soverini S., Blood 2011	[17]
	Diagnoses and treatment of primary MDS	Malcovati L., Blood 2013	[61]
	Flow cytometry in MDS	van de Loosdrecht A., Haematologica 2009 Della Porta M. G., Haematologica. 2012 Westers T. M., Leukemia. 2012	[18] [19] [20]
MPN	Revised response criteria for myelofibrosis	Tefferi A. Blood 2013	[62]
	Revised response criteria for ET and PV	Barosi G., Blood 2013	[47]
	Response criteria for ET and PV	Barosi G. Blood 2009	[21]
	Resistance and Intolerance definition in PV and MF	Barosi G. BJH 2010	[22]
	MPN management recommendations	Barbui T., JCO 2011	[23]
WP10-13	Optimal RT-PCR for Diagnosis of MRD in JAK2-V617F-associated MPNs: joint ELN/MPN&MPNr-EuroNet study	Jovanovic J., Leukemia 2013	[63]
	Development of a reporting software package	Østergaard M., Leukemia 2011	[24]
	Immunophenotyping of AL and lymphoproliferative disorders	Béné M.C., Leukemia 2011	[25]
	Microarray Innovations in Leukemia Study	Haferlach T., JCO 2010,	[26]

Transplan- tation	Group (Mile Study)	Mills K., Blood 2009	[27]
	The Interlaboratory ROBustness of Next-generation sequencing (IRON) study	Kohlmann A, Leukemia 2011 Kohlmann A., Leukemia 2010	[28] [29]
	Gene expression profiling recommendations	Kohlmann A., Br J H, 2008	[30]
	Microarray analyses guidelines	Staal F. J. T., Leukemia 2006	[31]
	Proposals for standardization for cytogenetic analyses	Haferlach C., GCC 2007	[32]
	WT1 PCR standardization	Cilloni D., JCO 2009	[33]
	Consensus morphology collection	www.leukemia-net.org	
	Prophylaxis and treatment of graft-versus-host disease	Ruutu T., BMT 2014	[64]
	Transplant-associated microangiopathy recommendations	Ruutu T., Haematologica 2007	[34]
	Supportive Care	Stem cell transplantation recommendations	Styczynski J., BMT 2008 Dreger P., Leukemia 2007 De Witte T., Haematologica 2006
Recommendations for management of infections		Styczynski J., BMT 2009 Ljungman P., BMT 2008 Herbrecht R., EJC 2007; Bucaneve G., EJC 2007; Marchetti O., EJC 2007 Maertens J. A. EJH 2007 Ljungman P., BMT 2005	[38] [39] [40] [41]
European guidelines for prevention and management of influenza in HSCT (ECIL-4)		Engelhard D., Transpl Infect Dis 2013	[48]
European guidelines for diagnosis and treatment of adenovirus infection (ECIL-4)		Matthes-Martin S., Transpl Infect Dis 2012	[49]
Guidelines for diagnosis and treatment of HRSV, PV, MPV, RV, and CV (ECIL-4)		Hirsch HH., Clin Infect Dis 2013	[50]
Guidelines for diagnosis and treatment of mucormycosis (ECIL 3)		Skiada A., Haematologica 2013	[51]
ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases		Arendrup MC., BMT 2012	[52]
Meta-analysis of β -Glucan antigenemia assay for the diagnosis of invasive fungal infections (ECIL-3)		Lamoth F., Clin Infect Dis 2012	[53]
ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases		Marchetti O., BMT 2012	[54]
ECIL 3-2009 update guidelines for antifungal management		Castagna L., BMT 2012	[55]
European guidelines for antifungal management: summary of the ECIL 3--2009 update	Maertens J., BMT 2011	[56]	